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ABSTRACT
Numerous studies have explored the effects of morphine on cognitive function, while  
knowledge concerning methadone is scarce. This study is the first in line, being part 
of a newly started project. The aim of this study was to examine whether long-term 
administration of methadone results in deficits in performance in the Novelty-test and 
changes in phosphorylation of  calcium/calmodulin kinase II (CaMKII) and 
extracellular signal-regulated kinase (ERK) in the hippocampus. Rats were 
administrated (sc) methadone, morphine or saline once per day for three weeks 
(2.5-10 mg/kg), and novelty-tested one hour and one week after the last injection. 
Western blotting was performed on homogenate from hippocampus, taken out directly 
after the novelty-testing, to detect levels of phosphorylated CaMKII (p-CaMKII) and 
ERK (p-ERK). p-CaMKII was significantly down-regulated one week after the last 
injection of methadone, while no significant difference in p-ERK was observed. There 
were no significant differences between the groups in the novelty-test one week after 
the last injection, while one hour after the last injection the animals were to affected 
by the methadone to perform the test. Our findings indicate that long-term methadone 
exposure may specifically affect protein phosphorylation, but don’t seem to have a 
persistent effect on novelty-exploration. This may also be due to the Novelty-test not 
being sensitive enough to pick up small differences between the exposed groups and 
the control group. 
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ABBREVIATIONS 
AMPA receptor - α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor
Ca2+ - calcium ion
CaMKII - Calcium/calmodulin kinase II
cAMP - Cyclic adenosine monophosphate
ERK - Extracellular signal-regulated kinase 
HRP - Horseradish peroxidase 
LC-MS - Liquid chromatography-mass spectrometry
LTP - Long-term-potentiation
MAPK - Mitogen activated protein kinase
MMT - methadone maintenance therapy
MOR - µ-opioid receptor
NIPH - Norwegian Institute of Public Health
NMDA receptor - N-methyl-D-aspartate receptor  
SDS-PAGE - sodium dodecyl sulphate polyacrylamide gel electrophoresis
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1. INTRODUCTION
Methadone is a drug used in the rehabilitation of heroin addicts and has been used for 
the last 40 years (Dole and Nyswander, 1965). There are about 12 million heroin 
addicts in the world (UNODC, 2008). In Norway the corresponding number is 
12-15000 (Berg, 2008), and about 4700 of these are taking part in a rehabilitation 
program (Bretteville-Jensen and Amundsen, 2006; Bye, 2009). During the next few 
years this number will probably increase. Despite the widespread use of methadone in 
treatment of opioid-dependent people, little is known about its acute and chronic 
effects on cognitive functions, such as learning and memory formation (Curran et al., 
2001). 
1.1 Methadone
Methadone is a synthetic opioid, which was first synthesised as a morphine substitute 
during World War II in Germany to relieve severe pain (Tober and Strang, 2003). 
Methadone exerts its analgesic and narcotic effects by binding to the µ-opioid 
receptor (MOR) (see section 1.1.3).
1.1.1 General structure  
Methadone exists in two enantiomeric 
forms, R and S (Sim, 1973). The racemic mixture is 
the form commonly used clinically. The R-form has 
a 10-fold higher affinity for the MOR compared to 
the S-form (Taracha et al., 2006; Trescot et al., 
2008). Both the R- and the S-form have been 
shown to have N-methyl-D-aspartate receptor 
(NMDA receptor) antagonist activity (Callahan et 
al., 2004; Trescot et al., 2008). The S-form is also 
able to inhibit re-uptake of serotonin and 
norepinephrine from the synaptic cleft (Trescot 
et al., 2008).  
Fig. 1-1 Chemical structure of methadone
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Methadone has a half-life of 24-48 hours in opiate-dependent people, showing large 
individual variation (Curran et al., 2001). This half-life is considerably longer than 
that of morphine, 2-3.5 hours (Trescot et al., 2008), and much longer than the plasma 
half-life of heroin, which is approximately 5 minutes (Pichini et al., 1999). In rats, the 
half-life of methadone is about 3-4 hours (Misra et al., 1973), while morphine has a 
half-life of approximately 120 minutes (Iwamoto and Klaassen, 1977). The metabolic 
rate vary greatly between individuals, and is apparently due to genetic variability in 
the presence of cytochrome P450 enzymes in the liver (Trescot et al., 2008). 
Methadone is widely distributed in the tissue and highly bound to proteins, perhaps in 
the range 60-90% (Corckery et al., 2004). 
1.1.2 Use in methadone maintenance therapy
Methadone was first used in methadone maintenance therapy (MMT) in 1965 (Dole 
and Nyswander, 1965), and is still a cornerstone in society’s efforts to reduce 
problems with heroin abuse. Methadone binds to opioid receptors with high affinity 
and prevents other opioids, like heroin, binding to the receptor (Tober and Strang, 
2003). Because of the long half-life of methadone, one daily dose can maintain a 
steady state in the patients (Curran et al., 2001). Due to the large individual variations 
in methadone metabolism, patients receive different doses, usually between 80-120 
mg/day (Joseph et al., 2000), but doses of up to 700 mg/day have been reported 
(Leavitt et al., 2000). The right dosage of methadone will not give the subject any 
form of «rush», nor any abstinence or craving for heroin (Sim, 1973). 
Morphine, which has a similar mechanism of action as methadone, is known to affect 
memory processes (Prosser et al., 2006). It is therefore likely that methadone also 
may have negative effects on cognitive functions.
Despite its extensive use, possible negative side-effects of methadone consumption 
have been poorly investigated. Methadone-maintained patients perform significantly 
worse than controls on attention, information processing, short-term memory, long-
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term memory, and problem solving (Darke and Ross, 1997). It is suggested that at 
least some of the reason for this is the use of methadone, rather than other factors 
associated with the addicts’ lifestyle (e.g. poor dietary habits, repeated head injury, 
overdoses, concurrent abuse of alcohol and other drugs). It seems evident that an 
optimal cognitive function is crucial for a positive rehabilitation outcome (Spiga et 
al., 2008). To our knowledge, there are no studies published on controlled randomised 
long-term methadone administration to a non-drug using human population with 
cognitive outcome measures. Obvious ethical considerations might have contributed 
to this lack of studies in healthy subjects. More surprisingly is the absence of 
behavioural and toxicological effects studies in experimental animals. 
1.1.3 mu ‐ opioid receptor
Opioids are a class of chemical substances that mediate their effect(s) through opioid 
receptors. The main use of opioids is in pain relief. The group consists of natural 
opiates (alkaloids of the opium plant, e.g. morphine), semi-synthetic opiates (e.g. 
heroin) and synthetic opioids such as methadone (Callahan et al., 2004). 
Opioid receptors are signal transducers located in the cell membrane, which exerts 
their effect through G-protein linked signalling pathways (Martini and Whistler, 2007; 
Henriksen and Willoch, 2008). There are 3 subgroups of opioid receptors, the µ, κ, 
and δ opioid receptor (Ree et al., 1999; Henriksen and Willoch, 2008; Trescot et al., 
2008). Both methadone and morphine bind to the µ-subtype (Taracha et al., 2006; 
Martini and Whistler, 2007; Henriksen and Willoch, 2008), although with different 
affinity (Kristensen et al., 1995; Liu et al., 1999). 
Stimulation of the MOR activates intracellular second-messenger systems regulating 
metabolic enzymes, ion channels, transcription (Wallisch et al., 2007; Henriksen and 
Willoch, 2008), and a number of protein kinases, including Calcium/calmodulin 
kinase II (CaMKII) and Mitogen activated protein kinase (MAPKs) (Ma, 2003).  
Acute activation of the receptor inhibits adenylyl cyclase, decreases Calcium (Ca2+) 
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influx and increases Potassium (K+) efflux (Mestek et al., 1995), while chronic 
stimulation has the opposite effect (Avidor-Reiss et al., 1996).
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Plasma membraneMOR
GAdenylyl 
Cyclase
Second Messengers
(cAMP)
Protein  Kinase Signal Transduction Pathways
(CaMKII, MAPK)
Transcription Factors
Changes in Gene Expression
Cytoplasmic events
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Fig. 1-2 Simplified schematic figure of signal transduction through the MOR. MORs modulate the 
levels of second messengers (e.g. cAMP and Ca2+), which in turn regulate the activity of different 
protein kinases. Such kinases affect the function of proteins located in the cytoplasm, plasma 
membrane, and the nucleus. Among membrane proteins affected are ligand-gated and voltage-gated 
ion channels. Protein kinases may also affect the activity of transcription factors. Figure modulated 
from Koob and Moal (2005).
1.2 Learning and memory
Memory is the mental ability to store, retain and recall information. Learning is 
defined as acquiring new knowledge, behaviours, skills, values, preferences or 
understanding (Lynch, 2004). 
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Both learning and memory are examples of neuronal plasticity, the ability of the brain 
to change function and structure in response to internal or external stimuli (Miyamoto, 
2006). In 1973, Bliss and Lømo identified long-term potentiation (LTP) (Silva, 2003; 
Miyamoto, 2006). LTP describes long-lasting changes in the communication between 
two neurons that results from simultaneous stimulation (Cooke and Bliss, 2006). LTP 
is widely considered to be one of the major mechanisms underlying learning and 
memory (Pu et al., 2002; Lynch, 2004; Thomas and Huganir, 2004; Cooke and Bliss, 
2006; Rudy, 2008), and involves a signal transduction cascade that includes release of 
glutamate, activation of NMDA receptor and α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) receptor, Ca2+ entry, and activation of intracellular 
signalling molecules/cascades (Miyamoto, 2006). 
1.2.1 Hippocampus 
The hippocampus is located inside the medial temporal lobe of the cerebral cortex 
(fig. 1-3) and is part of the limbic system. The limbic system has a variety of 
functions including emotions, behaviour, long-term memory and olfaction. It has been 
shown that the hippocampus plays a vital role in formation of memory (Pu et al., 
2002; Lynch, 2004). 
Fig. 1-3 Location and relative size of hippocampus in the rat brain and in the human brain (Missler 
and Runkel, 2009)
The hippocampus has many of the same functions in rats as in humans, i.e. memory 
processing and navigation (Burgess et al., 2004). By inducing hippocampal damage in 
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animals, severe deficits in spatial learning and memory are produced (Eichenbaum, 
2000). 
Lifelong neurogenesis occurs for cells in the hippocampal dentate gyrus in rodents, 
primates and man (Altman and Das, 1965; Eriksson et al., 1998; Gould et al., 1999). 
It seems that new neurons are related to important functions in learning and memory 
(Gould et al., 1999; Praag et al., 1999), and that opioids may have a negative impact 
by decreasing neurogenesis (Harburg et al., 2007). In rats, chronic administration of 
morphine reduces neurogenesis in the granular cell layer of the hippocampus by 
approximately 40% (Eisch et al., 2000). At least in vitro, the inhibitory effects of 
morphine on the proliferation of astroglia seems to be mediated directly through the 
MOR (Hauser et al., 1996), which the hippocampus expresses widely (Pu et al., 
2002). 
1.2.2 NMDA receptor  
The NMDA receptor is a ligand- and voltage-gated ion channel (Bear et al., 2007). 
Glutamate is the primary ligand, but the receptor has several binding sites for different 
modulators (Rudy, 2008). The receptor is widely distributed in the brain, especially in 
the hippocampus, and it is thought to play an important role in synaptic plasticity 
(Cooper et al., 2003; Wang et al., 2006; Rudy, 2008). 
The NMDA receptor is activated by the combined action of cell membrane 
depolarisation and glutamate binding (Rudy, 2008). Activation of the receptor results 
in Ca2+entry and downstream activation of several proteins, e.g. CaMKII (Reul and 
Chandramohan, 2007), which are important for LTP induction (Miyamoto, 2006; 
Rudy, 2008). Methadone may affect these processes by acting as an antagonist on the 
NMDA receptor.
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Fig. 1-4 Simplified schematic figure of signal transduction through the NMDA receptor. Glutamate is 
released from the presynptic neuron, passes through the synaptic cleft and binds to the NMDA receptor 
and the AMPA receptor. Increased influx of sodium (Na+)through the AMPA receptor leads to a 
depolarisation of the membrane, and removal of magnisium (Mg2+) from the NMDA receptor channel. 
Opening of the NMDA receptor allows Ca2+ influx, which can bind to calmodulin, and further activate 
proteins like CaMKII. Figure modulated from Rudy (2008).
1.3 CaMKII and ERK in learning and memory formation
A major regulatory mechanism of signal transduction is protein phosphorylation 
(Yamauchi, 2005). 
1.3.1 CaMKII
The Ca2+ ion is an universal secondary messenger in eukaryotic cells. It plays an 
essential role in the basic operation of neurones through synaptic communication. The 
predominant intracellular receptor of Ca2+ is calmodulin (Yamauchi, 2005). The Ca2+/
calmodulin complex phosphorylates the Ca2+/calmodulin-dependent protein kinase II 
(CaMKII) (Miyamoto, 2006). CaMKII exists in at least 5 isoforms throughout the 
body, with two of them being expressed in nervous tissue (α- and β-isoform) (Lou et 
NMDAAMPA
Mg2+
Glutamate
Ca2+Na+
Ca2+/Calmodulin
CaMKII
Presynaptic
neuron
Postsynaptic
neuron
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al., 1999). Phosphorylated CaMKII (p-CaMKII) has a wide substrate specificity and 
phosphorylates more than 50 different proteins (Yamauchi, 2005). Accordingly, 
CaMKII regulates several different neuronal functions, including neurotransmitter 
synthesis, neurotransmitter release, modulation of ion channel activity, cellular 
transport, cell morphology and neurite extension, synaptic plasticity, and gene 
expression (Yamauchi, 2005). There is a large body of evidence indicating that 
CaMKII plays an important role in LTP (Nicoll and Malenka, 1999).
CaMKII is highly expressed in the hippocampus in both man and rodents (Silva, 
2003), but also in other parts of the brain (Fukunaga and Miyamoto, 2000; Yamauchi, 
2005). The kinase constitutes about 2 % of the total protein amount in the 
hippocampus (Schulman, 1993). Genetic deletion of α-CaMKII in rats showed 
impaired hippocampal LTP, and impaired spatial learning in a hippocampal dependent 
task (Silva et al., 1992; Yamauchi, 2005). 
CaMKII can phosphorylate both NMDA receptors and AMPA receptors (Fukunaga 
and Miyamoto, 2000). This activation of the receptors may facilitate insertion of 
AMPA receptors in the plasma membrane and/or increase the conductance of existing 
channels (Cooke and Bliss, 2006), stimulating LTP. 
 
1.3.2 ERK
The Extracellular signal-regulated kinase (ERK) MAP kinase signalling pathway 
plays a critical role in learning, memory and other cognitive processes (Thomas and 
Huganir, 2004; Davis and Laroche, 2006; Samuels et al., 2009). ERKs are activated in 
response to a number of different extracellular stimuli e.g. Ca2+ (Thomas and Huganir, 
2004; Cammarota et al., 2008) and CaMKII (Lynch, 2004), and activate several 
downstream proteins. Both activation of the NMDA receptors and increased release 
from intracellular storage are responsible for the increase in intracellular Ca2+ 
concentration (Reul and Chandramohan, 2007), which may activate ERK. 
The ERK family consists of 5 different isoforms, where ERK1 and 2 has been linked 
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to LTP formation (Cammarota et al., 2008). Inhibition of the ERK2 signalling 
pathway has been shown to block both early and late LTP in the hippocampus (Lynch, 
2004; Cammarota et al., 2008)
ERK1 and 2 share 84% sequence identity and have the same substrate specificity. 
ERKs are most highly expressed in neurons compared to other cell types, and the 
relative expression of ERK2 is greater than that of ERK1 (Samuels et al., 2009).  
 
1.4 Animal models on hippocampal function
There are several tests available for measuring hippocampal learning and memory. 
The most commonly used is the Morris Water Maze, which map spatial memory 
(Morris, 1984). In the present work, we have used a Novelty-test. In this test, both the 
preference for novelty, exploratory activity and 
locomotor activity are measured (Myhrer, 1988). 
The test does not involve elements of reward, but is 
based on the rodents’ innate tendency to explore 
novel objects ahead of familiar ones. 
The animal species most commonly used in these 
tests are rats. This is because of their explorative 
nature and natural curiosity.
1.5 Animal research and ethics 
The research presented in this thesis could not have been conducted without the use of 
animals. The purpose of animal research is to investigate biological and medical 
questions related to the health of humans and animals (Hem et al., 2001). Animal 
research in Norway is regulated by the animal rights law given by the agriculture 
department. The law states that animal research cannot be conducted without approval 
from the National Animal Research Authority (Smith, 1999). The possible suffering 
of the animals must be weighed against the probable gain in each study. Alternatives 
Fig. 1-5 Picture showing housing of Wistar rats. 
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must always be considered, and the level of pain must be minimised. All animals 
exposed to large sufferings which cannot be eased, must be put to sleep immediately. 
Animal research can only be conducted with the necessary approvals; approved 
facilities, an approved responsible person and an approved project description 
(Medline Plus Hem et al., 2001). At the Norwegian Institute of Public Health (NIPH) 
these criteria are fulfilled. 
1.6 Aims of the study
There is a widespread hypothesis that methadone affect cognitive functions. However, 
a vide variety of factors may contribute to the cognitive impairment observed in 
methadone users (e.g. poor dietary habits and health status, concurrent abuse of 
alcohol and other drugs, opiate overdoses; (Darke and Ross, 1997; Nazrul et al., 
2002), and controlled randomised long-term administration of methadone to a non-
drug abusing human population is restricted by ethical considerations. A feasible 
approach to study the possible negative effects of methadone on cognitive functions is 
therefore experimental animal studies. Such studies can also more easily characterise 
the underlying neurobiological mechanisms. 
In this thesis we have combined in vivo studies and ex vivo experiments to answer the 
following specific research questions: 
1. How is novelty-preference (attention) in rats affected after long-term administration 
of methadone?
2. Is the possible impaired cognitive performance a result of changes in intracellular 
signalling molecules?
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2. MATERIALS AND METHODS
2.1 Animals and Chemicals 
2.1.1 Animals
Adult, male Wistar rats (n = 54), weighing 270 ± 15 g when acquisition started, were 
delivered by a commercial supplier (Møllegaard Breeding laboratories, Denmark). On 
the day of arrival the rats were approximately 60-80 days old. The rats were housed in 
a climatized vivarium (21°C, illuminated from 08:00 to 20:00 h), and had free access 
to commercial rat pellets and water. On arrival the rats were placed 2-3 rats per cage. 
After 5 days they were separated into their own cage (38 cm x 22 cm x15 cm) in 
which they lived during the injection period and the behavioural testing. All animals 
were handled individually by exploring a tabletop for ~3 min every day for 2-4 
weeks. 
All experiments were conducted during the light period of the day-night cycle 
between 08:00 and 14:00 h. The experiments were approved by The National Animal 
Research Authority.
2.1.2 Chemicals
Listed according to manufacturer:  
BDH Laboratory Supplies (Poole, England)
AnalaR® ammonium formate
BioRad (Oslo, Norway)
30% Acrylamide/Bis solution 29:1, Ammonium Persulphate (APS), Precision Plus 
Protein Standard, Sodium dodecyl sulphate (SDS), TEMED, Tris(hydroxymethyl)-
aminomethane (Tris-base)
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Cell Signalling (Oslo, Norway)
Anti-biotin (HRP-linked antibody), Biotinylated Protein Ladder, anti-CaMKII, anti-
Phospho-CaMKII
Lab-Scan (Gliwice, Poland)
Acetonitrile, Methanol
Merck (Drammen, Norway)
Folin Ciocalteus Reagens, Leupeptin Hemisulphate Salt, Sodium Hydroxide (NaOH), 
2-propanol, Sodium chloride (NaCl), Sucrose
Millipore (California, USA)
Reblot Mild
NMD (Oslo, Norway)
Morphine hydrochloride (Morphine HCl 3H2O; MW 375.9)
Pierce (Rockford, USA)
SuperSignal West Dura Luminol, SuperSignal West Dura Stable Peroxide Buffer
Santa Cruz Biotechnology Inc (Heidelberg, Germany)
Anti-ERK, Anti-Phospho-ERK, Goat Anti-Mouse IgG-HRP, Goat Anti-Rabbit IgG-
HRP
 
Sigma (Oslo, Norway)
Albumin bovine serum (BSA), Aprotinin, Bromphenol blue, Copper(II)sulphate pent 
hydrate (CuSO4), Glycerol 2-phosphate disodium salt hydrate, Mercaptoethanol, (±)-
Methadone hydrochloride (Methadone HCl; MW 345.9), Pepstatin A, 
Phenylmethanesulfonylfluoride (PMSF), Ponceus S, Potassium Sodium Tartrate Tetra 
hydrate (K(Na)tartat), Skim Milk Powder, Sodium Carbonate (Na2CO3), 
Trichloroacetic acid, Trizma hydrochloride, 5-sulfosalicylic acid dehydrate (Tris-HCl)
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2.2 Methods 
2.2.1 Administration of methadone 
The rats were randomly assigned to one of three experimental groups. Each 
experimental group consisted of 7-10 animals. The animals were acclimatised to the 
animal house conditions for 5 days before the injection regime started. The rats were 
injected subcutaneous (sc) with either methadone or morphine. 0.9% NaCl was used 
as control.  The animals were subjected to daily handling in the same room by the 
same experimentator. The rats were weighed before, during and after the injection 
regime. 
The first two days, the rats received 2.5 mg/kg, the next three days the dose was 
increased to 5 mg/kg, and the last two weeks they were given 10 mg/kg.  All 
injections were given in total volumes of  0.01 ml/10 g rat. The injections were given 
Monday to Friday in the morning (8 am - 11 am).  
Fig. 2-1 Injection course. One daily injection was given Monday to Friday for 3 weeks. The two first 
days the dose was 2.5 mg/kg, the next three days the dose was 5 mg/kg, and the last two weeks the dose 
was 10 mg/kg. Control animals received 0.9% NaCl. 
2.2.3 Novelty‐test
Apparatus:
The behavioural testing was carried out in a Plexiglas cage (56 cm x 34 cm x 20 cm) 
previously described (Myhrer, 1988). The floor was divided into 18 equal squares (9 
cm x 11 cm). In the middle of the cage three identical aluminium cubes (5 cm x 5 cm 
x 5 cm) were evenly distributed in fixed positions (neutral objects). The novel object 
differed in that two of its sides were uneven with tracks (visual/tactile stimuli) and its 
size was smaller (4.5 cm x 4.5 cm x 4.5 cm). All the four objects were painted grey. 
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The only light in the test room was an office lamp (15 W) placed 60 cm above the 
cage. The testing room was provided with a fan to make white noise. 
Fig. 2-2 Picture showing the rat in the test apparatus with three neutral objects. 
Procedure:
The day before testing, the rats were allowed to individually explore the empty test 
cage for 15 min. Each animal was tested individually. 
Prior to the testing of each rat, the apparatus and objects were carefully washed with 
soap (PEP) dissolved in water and allowed to dry. The test was divided into two 
phases. In phase 1, the rat was presented with the three neutral objects. In phase 2, the 
neutral object positioned in the middle was replaced by the novel object. Phase 1 and 
phase 2 lasted for 5 min, and was interrupted by a 10 min break, where the animal 
was placed back in its home cage. The following behaviours were recorded: number 
of sec in contact with each object, number of squares traversed (locomotor activity), 
and number of times animal reared (standing on their rear legs). Exploration of an 
object was defined as directing the snout towards the object at a distance of 1 cm or 
less. Bodily touch other than the snout was not considered as exploratory behaviour. 
Preference for novelty was calculated as the difference between exploration of the 
novel object versus the mean exploration of the two neutral objects in phase 2.
2.2.4 Acquiring samples and sample preparation
After the behavioural testing, the animals were decapitated under light CO2 
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anaesthesia and the brains removed. The hippocampus was dissected on ice and 
directly frozen in liquid nitrogen (-196°C). The samples, and the rest of the brain 
tissue, were stored in a freezer at -80°C until use.
Homogenisation:
The hippocampus was weighed and homogenised (450 rpm) in homogenisation buffer 
(0.32 M sucrose, 0.01 mg/ml leupeptin, 0.01 mg/ml aprotinin, 0.005 mg/ml pepstatin 
A, 0.5 mM PMSF) to make a 5% homogenate. Aliquots of 50 µl homogenate were 
frozen (-80°C) for later analysis.
2.2.5 Protein analysis – Lowry
The amount of protein in the hippocampus homogenate was determined as described 
(Lowry et al., 1951). In this method there will be a colour reaction between 
phosphomolybdic ions and proteins, if the proteins first are exposed to copper (Cu2+) 
in an alkaline environment. 
3.5 µl of the 5% homogenate was added 200 µl dH2O. The reaction was started by 
adding 1 ml application solution (2% Na2CO3 in 0.1 M NaOH, 0.5% CuSO4x5H2O, 
1% K(Na)tartrate; 98:1:1). Each sample was mixed well. After 10 minutes, the 
reaction was stopped by adding 100 µl stop reagent (Folin-Ciocalteus reagent, dH2O; 
1:1) and mixed well. Three parallels were made of each sample. The samples were 
placed on the bench for a minimum of 30 min before the absorbance was read at 750 
nm by a spectrophotometer (Lambda 3; Perkin Elmer). 
The standards were: blind (0 µg BSA), standard 1 (5 µg BSA), standard 2 (10 µg 
BSA), standard 3 (15 µg BSA), standard 4 (20 µg BSA), standard 5 (25 µg BSA) and 
standard 6 (35 µg BSA). BSA was dissolved in dH2O. 
2.2.6 Western blotting
The presence of proteins was semi qualitatively demonstrated by Western blotting, as 
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described by Burnette (1981). The method includes the following steps: separation of 
proteins by gel electrophoresis, transfer of proteins from the gel to a nitrocellulose 
membrane, identification of proteins with specific monoclonal antibodies and 
visualisation of protein-antibody-complexes with chemiluminescense. 
Western blot samples:
50 µl of the 5% homogenate was mixed with 10 µl 10% SDS. Then 34 µl of a 3x 
sample buffer (0.015 mg/ml leupeptin, 0.015 mg/ml aprotinin, 0.0075 mg/ml 
pepstatin A, 0.7 mM PMSF) was added, and finally 3.6 µl mercaptoethanol was 
added. The samples were boiled for 5 min at 100 °C (under an outlet, due to the 
mercaptoethanol). The samples were mixed well between each step.
2.2.6.1 SDS-PAGE 
SDS-PAGE (sodium dodecyl sulphate polyacrylamide gel electrophoresis) is used to 
separate proteins according to molecular weight. By binding to SDS, the proteins 
become negatively charged. When voltage is turned on, the SDS-polypeptide will 
move through the polyacrylamide gel and be separated into different bands 
representing distinct molecular masses. The bands can be identified by using 
molecular weight standards and specific antibodies.
The glass plates were washed with 70% ethanol and dried before assembling the gel 
mould.
The 12% resolving gel (3.3 ml dH2O, 4.0 ml 30% Acrylamide/Bis solution 29:1, 2.5 
ml 1.5 M Tris (pH 8.8), 0.1 ml 10% SDS, 0.1 ml 10% APS, 0.004 ml TEMED) was 
prepared and pipetted between two glass plates, slowly to avoid bubbles. Then 100 µl 
2-propanol was carefully pipetted over the gel to make the surface smooth. The gel 
was left for 30 min to polymerise. 
After the resolving gel was polymerised, the 2-propanol was washed off with dH2O 
and the gel was dried carefully. The stacking gel (6.1 ml dH2O, 1.3 ml 30% 
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Acrylamide/Bis solution 29:1, 2.5 ml 0.625 M Tris (pH 6.8), 0.1 ml 10% SDS, 0.05 
ml 10% APS, 0.005 ml TEMED) was then prepared. This solution was pipetted on top  
of the separation gel. The comb was placed into the stacking gel which was left to 
polymerise (20-30 min). 
When the stacking gel was polymerised the comb was removed and the wells washed 
carefully with dH2O. The electrophoresis chamber was assembled, and filled with 1x 
electrophoresis buffer (25 mM Tris(hydroxymethyl)-aminomethane, 0.2 M glycine, 
3.4 mM SDS). The electrophoresis was performed at 100 V the first ~10 min and then 
at 200 V for ~1 hour. The gel electrophoresis was concluded before the proteins went 
out of the gel. Two standards were used, a visible molecular standard, Precision Plus 
Protein Standard, and a Biotinylated Protein Ladder. 
2.2.6.2 Blotting 
Electrophoretic separated proteins can be transferred from a gel to a nitrocellulose 
membrane by electroblotting, which is a direct electrophoretic transfer of proteins. 
When the SDS-PAGE finished running, the stacking gel was removed. The resolving 
gel was placed on top of a pre-soaked (in transfer buffer) membrane. Pre-soaked 
sponges, filter-papers, the gel and the nitrocellulose membrane were assembled as a 
«sandwich». All air bubbles were carefully removed. The chamber was then filled 
with 1x transfer buffer (25 mM Tris(hydroxymethyl)-aminomethane, 0.2 M Glycine, 
20% methanol). The transfer was performed at 70 V for 45-60 min. After blotting the 
membranes (blots) were put in Ponceus colour for 2 min to verify that the proteins 
had been transferred and that approximately the same amount of protein was present 
in each well.
2.2.6.3 Antibody exposure 
The following primary antibodies were used: anti-Phospho-CaMKII (1:2000), anti-
Phospho-ERK (1:1000), anti-CaMKII (1:1000) and anti-ERK (1:500 000). The 
secondary antibodies used were goat anti-rabbit IgG-HRP (1:5000), goat anti-mouse 
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IgG-HRP (1:5000) and anti-biotin HRP-linked antibody (1:5000).
The blots were pre-incubated in TBS (1.54 M NaCl, 1 M Tris-HCl) for 5 min before 
being incubated in blocking buffer (3% skimmed milk in TBS) for one hour to avoid 
unspecific binding. The blots were then incubated for 2 hours at room temperature or 
overnight at 4°C with the primary antibody. The next day, the blots were washed for 4 
x 10 min in cold TBS-T (1.54 M NaCl, 1 M Tris-HCl, 0.5% Tween 20), then 
incubated in blocking buffer for 30 min and exposed to the secondary antibody for 2 
hours at room temperature. After exposure to the secondary antibody the blots were 
washed for 3 x 10 min in cold TBS-T and then 1 x 10 min in TBS.
2.2.6.4 Detection
Super Signal is a chemiluminescent substrate for Horseradish Peroxidase (HRP). The 
reaction between the enzyme and the substrate results in light being emitted. The 
emitted light is proportional with the amount of target protein, and can be detected by 
a molecular imager. 
The blots were incubated in Super Signal detection solution (SuperSignal West Dura 
Luminol, SuperSignal West Dura Stable Peroxide Buffer; 1:1) for 5 min. Then the 
redundant fluid was removed and the blots were placed face down, on a plastic foil. 
The blots were wrapped in the plastic foil, and all air bubbles were removed before 
the blots were placed in a ChemiDoc XRS imager (BioRad; Norway). A luminescence 
image was captured every min for 10 min. 
2.2.6.5 Antibody stripping
The blots were rinsed with 1x TBS-T (2 x 10 ml), and exposed to 20 mL 1x Re-Blot 
Plus Mild Solution for 15-25 min. The blots were thereafter rinsed with 1x TBS-T (2 
x 10 ml), and incubated 2 x 5 min in 20 ml blocking buffer. The blots were now ready 
for another antibody exposure. 
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2.2.7 LC‐MS analysis 
The presence of methadone or morphine, in the brain tissue was investigated by LC-
MS analysis as described (Oiestad et al., 2007). LC-MS is a technique that combines 
the separation power of HPLC (high performance liquid chromatography) and the 
detection power of MS (mass spectrometry). 
Brain tissue was weighed and homogenised in ice-cold dH2O (1:2). 
100 µl brain homogenate was added 100 µl dH2O and 50 µl internal standard (5 µM 
methadone d9/morphine d9). The extractions were added to acetonitrile/methanol 
(85/15), mixed well and placed in the freezer for 10 min. Then the samples were 
centrifuged (4500 rpm, 10 min) before the organic phase was transferred to a 5 ml 
glass tubes. The samples were evaporated to dryness under N2 at 50°C (water bath), 
added to 100 µl of 3% acetonitrile/97% 5 mM ammonium format buffer (pH 3.1) and 
transferred to 0.3 ml plastic autosampler tubes.  
LC-MS analysis:
This is a well established analysis at The Division of Forensic Toxicology and Drug 
Abuse, Norwegian Institute of Public Health, and was conducted by department 
engineer Åse Ripel. 
LC-conditions:
Injection volume: 10 µl, mobile phase:  A; acetonitrile and B; 5 mM ammoniumacetat 
buffer pH 5, column: Xterra® MS  C18 (2.1 x 150 mm), column temperature: 35°C, 
software: Mass Lynx, flow rate: 0.3 ml/min, and runtime: 10 min.
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Table 2-1 showing the MS conditions
Positive mode (ES+), SIR
Start time: 2.5 min
Stop time: 10.0 min
Mass Cone (V) Coll (eV) Substance
310.0 25.00 20 Methadone
319.0 20.00 20 Methadone-d9 (internal standard)
286.0 45.00 20/40 Morphine
292.0 45.00 25.00 Morphine-d9 (internal standard)
2.2.8 Statistical analysis
All figures were constructed with SPSS (Version 16.0). All results are expressed as 
box-and-whisker plot, showing 5, 25, 50, 75 and 95 % cumulative relative frequencies 
(centiles). Outliers are not shown. The data analyses were performed with SPSS 
(version 16.0). Some of the data were not normally distributed, therefore the Kruskal-
Wallis test was used to compare the groups. The Kruskal-Wallis test is a non-
parametric test that compares several populations on the basis of independent samples 
from each population. The test ranks the responses from all groups together and then 
applies one-way ANOVA to the ranks rather than to the original observations. 
Pairwise comparison was used to determine which of the groups were different. P-
values ≤ 0.05 was stated as significant.
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3. RESULTS
3.1 Novelty‐test
The animals subjected to three weeks of methadone or morphine injections were 
tested in a novelty-test one hour and one week after the last injection.
3.1.1 Novelty‐test one hour after the last injection
One hour after the last injection, there was a difference in novelty-seeking between 
the groups (H = 11.75, 2 d.f., p ≤ 0.05, n = 7-8). The animals subjected to methadone 
had no novelty-seeking compared to the control animals (p ≤ 0.01, fig. 3-1).
Figure 3-1 Animals subjected to methadone (n = 8) for three weeks and tested one hour after the last 
injection showed no novelty-seeking. The morphine (n = 8) injected animals did not differ from the 
control group (n = 7). Novelty-seeking was measured as time in contact with novel object divided by 
the mean of time in contact with neutral objects in phase 2. ** p ≤ 0.01, Kruskal-Wallis, compared to 
control. 
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The locomotor activity of the groups differed from each other in both phases (phase 1: 
H = 20.5, 2 d.f., p ≤ 0.05, n = 7-8, phase 2: H = 16.3, 2 d.f., p ≤ 0.05, n = 7-8). The 
methadone injected animals showed little or no locomotor activity (p ≤ 0.05, fig. 
3-2a), and displayed «intoxication» behaviour such as increased salivation. The 
animals subjected to morphine ran around the test cage far more than the control 
animals and the run pattern was along the cage walls (not around the objects). The 
same differences were seen for rearings (standing on the rear legs, fig. 3-2b), a widely  
used measurement of explorative behaviour (phase 1: H = 18.0, 2 d.f., p ≤ 0.05, n = 
7-8, phase 2: H = 11.6, 2 d.f., p ≤ 0.05, n = 7-8).
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Figure 3-2 a) Locomotor activity and b) number of rearings in animals subjected to saline, methadone 
or morphine for three weeks and tested one hour after the last injection. The locomotor activity was 
measured by counting number of squares crossed in each phase. There was a difference in locomotor 
activity in both phase 1 and 2 (n = 25). There was a significant difference in number of rearings in 
phase 1 and 2 (n = 25). * p ≤ 0.05, Kruskal-Wallis, compared to control phase 1. † p ≤ 0.05, Kruskal-
Wallis, compared to control phase 2. 
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The rats weighed 270 ± 1.5 g (n = 25) when the injections started (H = 3.88, 2 d.f., p 
> 0.05, n = 8-10). All the animals gained or maintained their weight during the first 
two weeks. The third week, the animals subjected to methadone showed a small 
reduction in body weight (average of 10 g, H = 7.27, 2 d.f., p ≤ 0.05, n = 3-8, fig. 
3-3). At the day of testing the animals weighed between  260 and 300 g.
Figure 3-3  Weight of animals subjected to saline, methadone or morphine for three weeks and novelty-
tested one hour after the last injection (n =25). There were no differences between the groups on the 
first day of injection. At day 19, the last day of injection, there was a difference between the groups. * p 
≤ 0.05, Kruskal-Wallis, compared to control. 
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3.1.2 Novelty‐test one week after the last injection
One week after the last injection, there were no significant differences in the novelty-
seeking between the groups (H = 1.06, 2 d.f., p > 0.05, n = 7-10, fig. 3-4). 
Figure 3-4 Novelty-seeking in animals subjected to methadone (n =7) or morphine (n = 8) for three 
weeks and tested one week after the last injection did not differ from the control (n = 10) animals. 
Novelty-seeking was measured as time in contact with novel object divided by the mean of time in 
contact with neutral objects in phase 2.  
There were no differences in locomotor activity between the groups in each phase 
(fig. 3-5a) when tested one week after the last injection (phase 1: H = 2.9, 2 d.f., p > 
0.05, n = 7-10, phase 2: H = 2.9, 2 d.f., p > 0.05, n = 7-10). There were no differences 
in the number of rearings between the three groups (fig. 3-5b, phase 1: H = 0.35, 2 
d.f., p > 0.05, n = 7-10, phase 2: H = 0.72, 2 d.f., p > 0.05, n = 7-10).
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Figure 3-5  a) Locomotor activity and b) number of rearings in animals subjected to saline, methadone 
or morphine for three weeks and tested one hour after the last injection. The locomotor activity was 
measured by counting number of squares crossed in each phase. There were no significant differences 
in locomotor activity or in the number of rearings between the groups in phase 1, or in phase 2 (n = 
25).
The rats weighed 274 ± 1.5 g (n = 29) when the injections started (H = 0.78, 2 d.f., p 
> 0.05, n = 8-12). All the animals gained or maintained th ir weight during the first 
week. The second and third week, the animals subjected to methadone maintained or 
showed a small reduction in body weight (average of 10 g, H = 4.5, 1 d.f., p ≤ 0.05, n 
= 3-4, H = 9.9, 2 d.f., p ≤ 0.05). After the injections were concluded (day 19), the 
animals exposed to methadone gained weight again. At the day of testing, the animals 
weighed between  300 and 340 g. Animals exposed to methadone or morphine had 
lower body weight compared to the control animals (H = 7.82, 2 d.f., p ≤ 0.05, n = 
8-10, fig. 3-6).
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Figure 3-6 Weight of animals subjected to saline, methadone or morphine for three weeks and novelty-
tested one week after the last injection (n =29). There were no differences between the groups at the 
first day of injection. At day 15 and 19, the last day of injection, the methadone injected animals 
differed from the control. At day 22 and 26, one week after the last injection, both the methadone group 
and the morphine group showed a weight difference compared to the control group. * p ≤ 0.05, 
Kruskal-Wallis, compared to control.
3.2 Western blotting
Western blotting was performed in hippocampus homogenate from the rats subjected 
to three weeks of methadone or morphine injection, as described in chapter 2.2.6. At 
least three parallels were performed for each sample.  
3.2.1 p‐CaMKII/CaMKII
The ability of methadone and morphine to induce phosphorylation of CaMKII was 
shown by use of a phospho-specific antibody that recognises phosphorylated Thr 286. 
The immunodetectable band of CaMKII was localised at 50 kDa. To compare the 
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level of p-CaMKII with the total amount of CaMKII protein, the p-CaMKII blots 
were reprobed with an anti-CaMKII antibody. Only small variations in the total 
amount of protein were observed. To be able to compare blots from different days, a 
control-sample were put on each gel. 
One hour after the last injection of methadone or morphine, there was no significant 
difference in p-CaMKII/CaMKII between the control group and the exposed groups 
(H = 1.73, 2 d.f., p > 0.05, n = 7-8). 
p-CaMKII →
CaMKII    →
Figure 3-7 Phosphorylation of  CaMKII (p-CaMKII) in methadone (n = 8) and morphine (n = 8) 
exposed animals compared to control (n = 7) animals novelty-tested one hour after the last injection. 
Representative immunoblots for p-CaMKII and total CaMKII are shown. There were no differences 
between the groups. Results are shown as p-CaMKII/CaMKII. Each sample was repeated at least three 
times.
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One week after the last injection, p-CaMKII/CaMKII was significantly down-
regulated in both methadone and morphine treated animals (H = 11.28, 2 d.f., p ≤ 
0.01, n = 7-10).
p-CaMKII →
CaMKII    →
Figure 3-8  Phosphorylation of  CaMKII (p-CaMKII) in methadone (n = 7) and morphine (n = 8) 
exposed animals compared to control (n = 10) animals novelty-tested one week after the last injection. 
Representative immunoblots for p-CaMKII and total CaMKII are shown. The methadone subjected 
animals and the morphine subjected animals were significantly different from the control group. 
Results are shown as p-CaMKII/CaMKII. ** p ≤ 0.01, Kruskal-Wallis, compared to control. Each 
sample was repeated at least three times.
3.2.2. p‐Erk/Erk
The ability of methadone and morphine to induce phosphorylation of ERK was shown 
by use of a phospho-specific antibody that recognises phosphorylated Tyr 204. The 
immunodetectable band of ERK2 was localised at 42 kDa. To compare the level of p-
ERK with the total amount of ERK protein, the p-ERK2 blots were reprobed with an 
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anti-ERK2 antibody. Only small variations in the total amount of protein were 
observed. To be able to compare blots from different days, a control-sample were put 
on each gel.
One hour after the last injection of methadone or morphine there was a significant 
difference in p-ERK/ERK between the control group and the exposed groups (H = 
7.3, 2 d.f., p ≤ 0.05, n = 7-8). Pairwise comparisons showed that the morphine 
exposed animals were significantly different from the control group (p ≤ 0.05), while 
the methadone exposed animals were not. 
p-ERK2 →        
ERK2    →    
Figure 3-9 Phosphorylation of ERK2 (p-ERK) in methadone (n = 8) and morphine (n = 8) exposed 
animals compared to control (n = 7) animals novelty-tested one hour after the last injection. 
Representative immunoblots for p-ERK2 and total ERK2 are shown. The morphine exposed animals 
were significantly different from the control group, while the methadone exposed animals were not. 
Results are shown as p-ERK/ERK. * p ≤ 0.05, Kruskal-Wallis, compared to control. Each sample was 
repeated at least three times.
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One week after the last injection, there were no differences in p-ERK/ERK in a) 
methadone treated animals (H = 0.12, 1 d.f., p > 0.05, n = 8), or in b) morphine 
treated animals (H = 1.71, 1 d.f., p > 0.05, n = 2-8) compared to the control animals. 
a)       b) 
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Figure 3-10 Phosphorylation of ERK2 (p-ERK) in a) methadone (n = 8) and b) morphine (n = 8) 
exposed animals compared to control (n = 2-8) animals novelty-tested one week after the last injection. 
Representative immunoblots for p-ERK2 and total ERK2 are shown. There were no significant 
differences between the methadone exposed animals and the control, or between the morphine exposed 
animals and the control. Results are shown as p-ERK/ERK. Each sample was repeated at least three 
times.  
3.3 LC‐MS analysis
The LC-MS analysis showed that animals subjected to three weeks of methadone 
injections and novelty-tested one hour after the last injection had methadone left in 
their brain tissue (n = 7). One week after the last injection there was no methadone (n 
= 7) left in the brain tissue. The morphine subjected animals had morphine left in the 
brain tissue when tested one hour after the last injection (n = 4), but no morphine left 
after one week (n = 8). Lowest detection level was set to 0.1 µM for both compounds.
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Table 3-1 LC-MS analysis of brain tissue from animals injected with methadone or morphine for three 
weeks. The animals tested one hour after the last injection had methadone and morphine left in the 
brain, while there was nothing left one week after the last injection (n = 4-8).
Time of testing 
(after the last 
injection)
Methadone (nmol/g) Morphine (nmol/g)
One hour 4.01 ± 1.07 0.51 ± 0.13
One week  
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4. DISCUSSION
4.1 Novelty‐test
One hour after the last injection, the methadone animals were too affected by the 
methadone to perform the novelty-test. The rats were immobile and showed 
«intoxication» behaviour  such as increased salivation. The LC-MS analysis showed 
that there was methadone in the brain tissue at this time of testing. This corresponds 
with the documented half-life of methadone in rats of 3-4 hours (Misra et al., 1973). 
The behaviour of the morphine subjected animals were different. During the testing 
they were hyperactive, running around the test cage not seeming to notice the objects. 
Morphine has been shown to cause hyperlocomotion in rats 1-2 hours after injection  
(Moriyama et al., 1991; Narita et al., 2004). The plasma half-life of morphine in rats 
is about 120 min (Iwamoto and Klaassen, 1977; Lee et al., 2005). 
One week after the last injection, there were no differences between the exposed 
groups and the control group. The LC-MS analysis showed that there was no 
methadone or morphine left in the brain tissue at this time of testing. 
In our lab at the Norwegian Institute of  Public Health (NIPH), the same test has also 
been conducted one day after the last injection of methadone (J.M. Andersen; 
personal communication). At this time, the animals showed a 50% reduction in 
novelty-seeking. Taken together, these results indicate that long-term exposure to 
methadone may affect the novelty-seeking in rats, one hour and one day, but not one 
week after the last injection. The most likely reason for not seeing differences 
between the groups one week after the last injection compared to the difference one 
day after the last injection, may be that the effects after long-term administration of 
methadone and morphine are reversible. This is in accordance with previous work, 
showing that opioids affect different functions linked to memory and learning, but 
that the changes may be reversed (Guerra et al., 1987; Ammon-Treiber et al., 2005). 
The most widely used test to map cognitive functions in rats is the Morris Water Maze 
(Morris, 1984). The water maze measures spatial learning and memory, which is a 
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hippocampal-linked function. In this test, the rat is required to swim repeatedly to an 
escape platform, hidden below the surface of opaque water (Morris, 1984). Novelty-
seeking differs from spatial learning, but is also linked to the hippocampus. In the 
novelty-test, the animal can choose not to explore the objects, while in the water maze 
the animals are forced to perform the test, which may result in higher sensitivity. 
Previous studies have shown that both rats injected with a single injection of 
methadone (Hepner et al., 2002) and repeated injections of methadone (Tramullas et 
al., 2007) show an impaired performance in the Morris Water Maze, when tested 15 
min and 2-24 hours after the last injection. The same has been seen for morphine 
(Gorji and Rashidy-Pour, 2008) and heroin (Tramullas et al., 2008). Because of the 
animal house facilities at NIPH, we were not able to employ the Morris Water Maze, 
and therefore used the Novelty-test. 
To familiarise the animals to the experimentator, the rats were subjected to daily 
handling. The rats were also allowed to explore the empty test apparatus the day 
before testing. This was done because animals not familiar with the experimentator or 
the test cage may not perform the behaviour-test due to fear. 
The methadone subjected animals were clearly affected the first hours after injection 
of the 5 and 10 mg/kg doses. As in humans, there are large individual variations in 
how well the rats tolerate methadone. During the injection period, four animals died 
(18%). Methadone depresses the brain stem’s respiratory control centre, reducing its 
sensitivity to carbon dioxide (CO2) (Corckery et al., 2004), leading to respiratory 
failure. This is the most likely cause of death in our animals. The deaths occurred the 
second week when the dose was increased from 5 mg/kg to 10 mg/kg, after two days 
of not receiving injections (Saturday and Sunday). The deaths may therefore, at least 
partly, be due to a sensitisation response to the drug (Handal et al., 2008). 
The animals injected with methadone for three weeks lost or did not gain weight the 
second and third week of the injection period. After the injections were terminated, 
the animals started gaining weight again. It has previously been shown that chronic 
methadone treatment results in a reduction of body weight in adult rats (Vajda et al., 
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1975). A great weight loss may affect how animals perform a behaviour-test. 
However, the weight loss in this study was less than 10%, which is seen as an 
acceptable weight loss (IACUC, 2004). Moreover, the number of rearings and the 
locomotor activity did not differ between the groups tested one week after the last 
injection. It seems therefore not probable that the moderate weight loss should have 
any effect on the novelty-seeking. 
Given that an average methadone dose to MMT patients (weighing 70 kg) is 80-120 
mg/day (Joseph et al., 2000) and that the average half-life is 24-48 hours (Curran et 
al., 2001), the daily doses used in our experiments (2.5-10 mg/kg, T1/2 = 3-4 h; Misra 
et al., 1973) are comparable with the doses administered to MMT patients. The 
difference is that over time the methadone concentrations in MMT patients will 
probably increase because of the long elimination half-life, while this is less likely in 
rats. 
Injection of methadone for three weeks to a rat that lives about 2-3 years, is a relative 
shorter exposure period compared to MMT patients that often use methadone for 
decades (H. Waal, SERAF; personal communication). In our laboratory, we have 
observed an effect after just three weeks and may question whether the effect would 
be even larger and more prolonged with a longer exposure period. Long-term 
methadone treatment has been associated with impaired cognitive functions (Darke et 
al., 2000; Specka et al., 2000). However, there has also been shown that the cognitive 
functions and overall health status of the MMT patients may be improved through a 
treatment program (Joseph et al., 2000). This may be due to a reduction in alcohol 
and other drug use, an improved dietary and health status, an expanding social 
network and more intellectual challenges (Soyka et al., 2008), and not directly to the 
methadone intake.
The rats injected with methadone showed a tendency to itch/scratch where the 
injections were put. This resulted in some small wounds in some of the animals. 
Methadone is known to cause local toxicity when given sc (Bruera et al., 1991; 
Mathew and Storey, 1999). We therefore switched weekly between giving the 
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injections on the left and right side of the lower part of the back. We were also careful 
not to touch the stamp before the needle had penetrated the skin, and wiped the 
injection site carefully after each injection. In other experiments, long-term exposure 
to opioids has been performed by administration in the drinking water (Tiong et al., 
1992; Sadava et al., 1997). However, we chose to use daily sc injection of methadone 
because this makes it easier to control the administered dose, and because methadone 
has an aversive taste (Chipkin and Rosecrans, 1978). 
4.2 Western blotting
There were no significant differences in the phosphorylation of CaMKII between the 
control group, methadone group and morphine group novelty-tested one hour after the 
last injection. One week after the last injection, there was a down-regulation of p-
CaMKII in both methadone exposed and morphine exposed animals. 
There was no difference in the phosphorylation of ERK between the animals 
subjected to methadone, novelty-tested one hour after the last injection, and the 
control group, while there was a significant difference between the morphine exposed 
group and the control group. Chronic morphine treatment has been shown to increase 
(Berhow et al., 1995), to decrease (Schulz and Höllt, 1998; Muller and Unterwald, 
2004), or not to influence (Narita et al., 2002) ERK phosphorylation. The down-
regulation observed in this study shows that morphine was not able to maintain ERK 
stimulation one hour after the last injection of a long-term exposure paradigm. 
Before the last test series, including 8 morphine injected and 2 saline injected animals, 
the animal house underwent changes in its procedures. Affecting this study was the 
ban of using CO2 anaesthesia, which made our animals stressed during the 
decapitation procedure. Stress is known to induce ERK phosphorylation (Reul and 
Chandramohan, 2007), and high expression of ERK has been seen in the 
hippocampus immediately after tail-shock stress (Yang et al., 2008). When comparing 
the intensity of p-ERK/ERK in the control animals decapitated with and without CO2, 
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the intensity was 10 times higher in the rats decapitated without CO2. Because of this 
high «background» we have decided to present the ERK results from this test series 
and the previous series separately to avoid masking a potential drug effect. There 
were no differences between the morphine or the methadone exposed groups 
compared to the control group one week after the last injection. This in accordance 
with another study using morphine (Valjent et al., 2004). However, to conclude on the 
effects on ERK, the experiment should be repeated. 
When comparing the western blot results from long-term methadone or morphine 
exposed animals tested one hour after the last injection and one week after the last 
injection, the phosphorylation of CaMKII was clearly different. One hour after the last 
injection there was still methadone and morphine left in the brain of the animal. When 
an opioid is present in the brain it will exert its effect, thereby maintaining a response, 
even though the «steady state» is changed. One week after the last injection, 
methadone or morphine was no longer present in the brain. The effect seen a week 
after the last injection may be due to modulation of cellular responses induced to 
compensate the long-term receptor stimulation, e.g. activation of adenylyl cyclase 
(Duman et al., 1988; Beitner et al., 1989; Nestler, 2004), decrease in G-protein 
coupling (Selley et al., 1997), desensitisation, receptor internalisation (Jordan and 
Devi, 1998), and receptor endocytosis (Whistler et al., 1999; Fábián et al., 2002; He 
and Whistler, 2005). When the drug is no longer present in the system, the cell may 
not be able to compensate for the induced changes, resulting in differences between 
drug treated animals and control animals.  
We cannot state if the effect seen on p-CaMKII by long-term methadone treatment 
(one week after the last injection) is caused by inhibition of the NMDA receptor or 
stimulation of the MOR, or both. A previous study supports the hypothesis that 
methadone may act through both the MOR and the NMDA receptor (Callahan et al., 
2004), due to the different receptor specificities of the R and S isomer. However, the 
effects of methadone and morphine observed on p-CaMKII, and also p-ERK levels, 
tend to go in the same direction, indicating that the MOR plays an important role 
since it is well established that morphine acts principally as a MOR agonist (Aderjan 
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and Skopp, 1998). 
Exposure to methadone or morphine did not affect the amount of total CaMKII or 
ERK, only minor differences were observed. Therefore, it seems unlikely that the 
reduced level of p-CaMKII/CaMKII one week after the last injection, and p-ERK/
ERK one hour after the last injection, is a result of cell death, even though a previous 
study has shown that chronic methadone treatment in mice increases expression of 
apoptosis-related proteins (Emeterio et al., 2006). A possible inhibition of the 
neurogenesis in hippocampus, as has been shown after chronic morphine exposure 
(Eisch et al., 2000), cannot be ruled out. 
4.3 Human relevance
MMT was intended to be a safe and effective medication to help heroin addicts 
starting a drug free life. However, the patients are maintained on methadone often for 
decades or even for life (Joseph et al., 2000). Despite of this, possible negative side-
effects of long-term methadone use, have been scarcely investigated.
Some of the limitations in the studies with MMT patients are the often small number 
of subjects, their drug use prior to and during the MMT, and the lack of suitable 
controls. Several studies show that MMT patients have an impaired cognitive 
performance (Darke and Ross, 1997; Darke et al., 2000; Mintzer and Stitzer, 2002), 
but whether this is due to methadone or other factors associated with the life-style is 
not known (Soyka et al., 2008). Because of the difficulties conducting studies with 
MMT patients and the ethical restrictions using healthy volunteers, experimental 
animal studies are a feasible approach in the search for more knowledge in this area. 
The outcome of future animal studies may affect the use of methadone in the 
rehabilitation of heroin addicts. If the studies reveal large damages due to long-term 
methadone administration, this may result in a need for additional treatment to 
counteract the effects. On the other hand, if future studies reveal little or no negative 
effect, this will be a support for continuing the treatment programs. Presently, the 
need for more knowledge is crucial. 
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5. Conclusion
This study shows that long-term exposure to methadone leads to a down-regulation of 
p-CaMKII in hippocampus one week after the last injection. No difference was seen 
in the level of ERK phosphorylation. We did not observe any effects in the novelty-
seeking one week after the last injection in animals subjected to methadone. The 
discrepancy between reduced phosphorylation of CaMKII and no effect in the 
novelty-test is not known, but may be due to low sensitivity of the behavioural test.
The rats were to affected by the drug to perform the novelty-test one hour after the 
last injection of methadone. No differences compared to the control, were observed in 
phosphorylation of CaMKII or ERK at this point. 
We found similar effects after morphine exposure as after methadone exposure, and 
may therefore speculate whether the MOR is the central receptor. More studies are 
needed to reveal the mechanisms involved. 
Proposal for further studies
Pre-expose the animals to heroin before exposing them to methadone to better 
resemble the human situation.  
Western blot analysis of brain tissue form animals decapitated several weeks after the 
last injection to see if three weeks exposure to methadone gives a persistent effect on 
protein phosphorylation. In the same context, phosphorylation of other proteins 
important for learning and memory would be interesting to investigate.
Pre-treatment with a MOR antagonist in vivo, and/or receptor studies ex vivo/in vitro, 
may reveal which receptor methadone exerts its effect through.
Instead of using the racemic mixture of methadone, it would be interesting to see if 
subjecting the animals to the different isomers would give a different result. 
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The Morris Water Maze could perhaps give a more accurate result, being more 
sensitive than the Novelty-test. 
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APPENDIX
Statistics 
Locomotor activity, raring and weight one hour after last injection
Ranks
Exposure N Mean Rank
Locomotion phase 1 Saline 8 12.50
Methadone 8 4.50
Morphine 8 20.50
Total 24
Test Statisticsa,b
Locomotion
Chi-Square 20.507
df 2
Asymp. Sig. .000
a. Kruskal Wallis Test
b. Grouping Variable: Exposure
Ranks
Exposure N Mean Rank
Locomotion phase 2 Saline 7 13.86
Methadone 8 4.50
Morphine 8 17.88
Total 23
Test Statisticsa,b
Locomotion
Chi-Square 16.318
df 2
Asymp. Sig. .000
a. Kruskal Wallis Test
b. Grouping Variable: Exposure
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Ranks
Exposure N Mean Rank
Rearing phase 1 Saline 8 13.75
Methadone 8 4.50
Morphine 8 19.25
Total 24
Test Statisticsa,b
Rearing
Chi-Square 18.015
df 2
Asymp. Sig. .000
a. Kruskal Wallis Test
b. Grouping Variable: 
Exposure
Ranks
Exposure N Mean Rank
Rearing phase 2 Saline 7 15.14
Methadone 8 5.44
Morphine 8 15.81
Total 23
Test Statisticsa,b
Rearing
Chi-Square 11.601
df 2
Asymp. Sig. .003
a. Kruskal Wallis Test
b. Grouping Variable: 
Exposure
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Ranks
Exposure N Mean Rank
Weight day 1 Saline 8 15.75
Methadone 10 13.30
3 8 11.50
Total 26
Test Statisticsa,b
Weight
Chi-Square 1.254
df 2
Asymp. Sig. .534
a. Kruskal Wallis Test
b. Grouping Variable: Exposure
Ranks
Exposure N Mean Rank
Weight19 Saline 4 10.75
Methadone 3 2.00
Morphine 8 8.88
Total 15
Test Statisticsa,b
Weight19
Chi-Square 7.271
df 2
Asymp. Sig. .026
a. Kruskal Wallis Test
b. Grouping Variable: 
Exposure
Locomotion, rearing and weight one week after last injection
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Ranks
Exposure N Mean Rank
Locomotion phase 1 Saline 10 10.85
Methadone 7 12.00
Morphine 8 16.56
Total 25
Test Statisticsa,b
Phase 1
Chi-Square 2.860
df 2
Asymp. Sig. .239
a. Kruskal Wallis Test
b. Grouping Variable: 
Exposure
Ranks
Exposure N Mean Rank
Locomotion phase 2 Saline 10 13.90
Methadone 7 9.07
Morphine 8 15.31
Total 25
Test Statisticsa,b
Locomotion
Chi-Square 2.938
df 2
Asymp. Sig. .230
a. Kruskal Wallis Test
b. Grouping Variable: Exposure
Ranks
Exposure N Mean Rank
Rearing phase 1 Saline 10 12.35
Methadone 7 12.50
60
Rearing phase 1 
Morphine 8 14.25
Total 25
Test Statisticsa,b
Rearing
Chi-Square .345
df 2
Asymp. Sig. .842
a. Kruskal Wallis Test
b. Grouping Variable: 
Exposure
Ranks
Exposure N Mean Rank
Rearing phase 2 Saline 10 13.00
Methadone 7 11.29
Morphine 8 14.50
Total 25
Test Statisticsa,b
Rearing
Chi-Square .717
df 2
Asymp. Sig. .699
a. Kruskal Wallis Test
b. Grouping Variable: 
Exposure
Ranks
Exposure N Mean Rank
Weight1 Saline 10 16.35
Methadone 12 13.79
Morphine 8 17.00
Total 30
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Test Statisticsa,b
Weight1
Chi-Square .780
df 2
Asymp. Sig. .677
a. Kruskal Wallis Test
b. Grouping Variable: 
Exposure
Ranks
Exposure N Mean Rank
Weight day 15 Saline 10 19.55
Methadone 9 8.11
Morphine 8 13.69
Total 27
Test Statisticsa,b
Weight
Chi-Square 9.862
df 2
Asymp. Sig. .007
a. Kruskal Wallis Test
b. Grouping Variable: Exposure
Ranks
Exposure N Mean Rank
Weight day 15 Saline 10 13.70
Methadone 9 5.89
Total 19
Test Statisticsa,b
Weight
Chi-Square 9.135
df 1
Asymp. Sig. .003
a. Kruskal Wallis Test
b. Grouping Variable: Exposure
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Ranks
Exposure N Mean Rank
Weight19 Saline 4 5.50
Methadone 3 2.00
Total 7
Test Statisticsa,b
Weight19
Chi-Square 4.500
df 1
Asymp. Sig. .034
a. Kruskal Wallis Test
b. Grouping Variable: 
Exposure
Ranks
Exposure N Mean Rank
Weight day 22 Saline 10 19.40
Methadone 8 8.00
Morphine 8 11.62
Total 26
Test Statisticsa,b
Weight
Chi-Square 10.593
df 2
Asymp. Sig. .005
a. Kruskal Wallis Test
b. Grouping Variable: Exposure
Ranks
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Exposure N Mean Rank
Weight day 22 Saline 10 13.05
Methadone 8 5.06
Total 18
Test Statisticsa,b
Weight
Chi-Square 9.991
df 1
Asymp. Sig. .002
a. Kruskal Wallis Test
b. Grouping Variable: Exposure
Ranks
Exposure N Mean Rank
Weight day 22 Morphine 8 6.56
Saline 10 11.85
Total 18
Test Statisticsa,b
Weight
Chi-Square 4.373
df 1
Asymp. Sig. .037
a. Kruskal Wallis Test
b. Grouping Variable: Exposure
Ranks
Exposure N Mean Rank
Weight26 Saline 10 18.80
Methadone 8 10.44
Morphine 8 9.94
Total 26
Test Statisticsa,b
Weight26
Chi-Square 7.823
df 2
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Asymp. Sig. .020
a. Kruskal Wallis Test
b. Grouping Variable: 
Exposure
Novelty-test one hour after last injection
Ranks
Exposure N Mean Rank
Novelty Saline 7 18.21
Methadone 8 6.31
Morphine 8 12.25
Total 23
Test Statisticsa,b
Novelty
Chi-Square 11.751
df 2
Asymp. Sig. .003
a. Kruskal Wallis Test
b. Grouping Variable: 
Exposure
Ranks
Exposure N Mean Rank
Novelty Saline 8 11.19
Methadone 7 4.36
Total 15
Test Statisticsa,b
Novelty
Chi-Square 9.307
df 1
Asymp. Sig. .002
a. Kruskal Wallis Test
65
b. Grouping Variable: 
Exposure
Ranks
Exposure N Mean Rank
Novelty Morphine 8 6.06
Saline 7 10.21
Total 15
Test Statisticsa,b
Novelty
Chi-Square 3.247
df 1
Asymp. Sig. .072
a. Kruskal Wallis Test
b. Grouping Variable: 
Exposure
Novelty test one week after last injection
Ranks
Exposure N Mean Rank
Novelty Saline 10 14.85
Methadone 7 11.93
Morphine 8 11.62
Total 25
Test Statisticsa,b
Novelty
Chi-Square 1.064
df 2
Asymp. Sig. .588
a. Kruskal Wallis Test
b. Grouping Variable: 
Exposure
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p-CaMKII/CaMKII one hour after last injection
Ranks
Exposure N Mean Rank
pCaMKII Saline 7 9.86
Methadone 8 11.12
Morphine 8 14.75
Total 23
Test Statisticsa,b
Intensity
Chi-Square 2.147
df 2
Asymp. Sig. .342
a. Kruskal Wallis Test
b. Grouping Variable: 
Exposure
p-CaMKII/CaMKII one week after last injection
Ranks
Exposure N Mean Rank
pCaMKII Saline 9 19.56
Methadone 8 9.94
Morphine 8 8.69
Total 25
Test Statisticsa,b
pCaMKII
Chi-Square 11.277
df 2
Asymp. Sig. .004
a. Kruskal Wallis Test
b. Grouping Variable: 
Exposure
Ranks
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Exposure N Mean Rank
pCaM Saline 9 12.00
Methadone 8 5.62
Total 17
Test Statisticsa,b
pCaM
Chi-Square 6.750
df 1
Asymp. Sig. .009
a. Kruskal Wallis Test
b. Grouping Variable: 
Exposure
Ranks
Exposure N Mean Rank
pCaM Morphine 8 5.00
Saline 9 12.56
Total 17
Test Statisticsa,b
pCaM
Chi-Square 9.481
df 1
Asymp. Sig. .002
a. Kruskal Wallis Test
b. Grouping Variable: 
Exposure
p-ERK/ERK one hour after last injection
Ranks
Exposur
e
N Mean Rank
Intensity 1 6 14.25
2 8 14.38
3 8 6.56
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Intensity
Total 22
Test Statisticsa,b
Intensity
Chi-Square 7.298
df 2
Asymp. Sig. .026
a. Kruskal Wallis Test
b. Grouping Variable: 
Exposure
Ranks
Exposure N Mean Rank
pERK Saline 6 10.50
Morphine 8 5.25
Total 14
Test Statisticsa,b
pCaM
Chi-Square 5.412
df 1
Asymp. Sig. .020
a. Kruskal Wallis Test
b. Grouping Variable: 
Exposure
p-ERK/ERK one week after last injection - methadone
Ranks
Exposure N Mean Rank
pERK Saline 7 7.57
Methadone 8 8.38
Total 15
Test Statisticsa,b
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pERK
Chi-Square .122
df 1
Asymp. Sig. .727
a. Kruskal Wallis Test
b. Grouping Variable: 
Exposure
p-ERK/ERK one week after last injection - morphine
Ranks
Exposure N Mean Rank
pERK Saline 2 8.00
Morphine 8 4.88
Total 10
Test Statisticsa,b
pERK
Chi-Square 1.705
df 1
Asymp. Sig. .192
a. Kruskal Wallis Test
b. Grouping Variable: 
Exposure
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